Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) disease is a newly identified condition with an estimated worldwide prevalence of < 100 patients. Patient interviews can ensure that what is important to patients is assessed in a clinical trial program. Due to the rare and potentially fatal nature of CHAPLE disease, interviews were conducted as part of the pozelimab clinical trial, rather than in a separate study before the trial. The aim of the interviews was to identify the key disease-related signs, symptoms, and health-related quality-of-life (HRQoL) impacts that are important and relevant to patients with CHAPLE disease.
Methods: Interviews were conducted with patients and/or caregivers at two timepoints (screening and Week 24) during the pozelimab trial to document the signs/symptoms and HRQoL impacts of CHAPLE disease, and document the most bothersome sign/symptom at screening. At Week 24, interviews gathered additional information on the patient experience from caregivers and patients (note: the impact of pozelimab treatment was also collected, though these results are presented elsewhere).
Results: Ten patients, aged 3-19 years, were enrolled in the trial; caregivers contributed to nine interviews. Thirty-one signs/symptoms and 65 HRQoL impacts were reported during the interviews. Abdominal pain, diarrhea, facial and peripheral edema/swelling, nausea, and vomiting emerged as the core signs/symptoms of CHAPLE disease (i.e., experienced by ≥ 90% of patients prior to treatment). The remaining 25 signs/symptoms were experienced by four or fewer (n ≤ 4, ≤ 40.0%) patients, and 15 were only reported by one patient each. Abdominal pain and facial edema were reported as the most bothersome signs/symptoms (n = 9, 90.0% and n = 1, 10.0%, respectively). The most frequently reported (i.e., ≥ 80% of interviews) HRQoL impacts were restricted diet (n = 10, 100.0%), sleep disruptions (n = 10, 100.0%), missing school (n = 9, 90.0%), ability to get dressed independently (n = 8, 80.0%), and difficulty engaging in play activities (n = 8, 80.0%).
Conclusions: The main finding from these patient interviews is the identification of six core signs/symptoms of CHAPLE disease: abdominal pain, diarrhea, facial edema/swelling, peripheral edema/swelling, nausea, and vomiting. The severity of the core signs/symptoms leads to substantial impacts on patients' lives.
Trial Registration: ClinicalTrials.gov, NCT04209634. Registered 20 December 2019 https://classic.
Clinicaltrials: gov/ct2/show/NCT04209634 .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11817392 | PMC |
| http://dx.doi.org/10.1186/s13023-024-03436-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade.
Front Nucl Med
August 2025
Department of Nuclear Engineering, University of Tennessee, Knoxville, TN, United States.
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms characterized by their overexpression of somatostatin receptors (SSTRs), which can be utilized for peptide receptor radionuclide therapy. This review provides a comprehensive update on the clinical trials of radiolabeled SSTR-targeting radiopharmaceuticals since 2020, with a focus on somatostatin receptor agonists and antagonists radiolabeled with Ga, F, Tc, Lu, Tb, Pb, Cu, and Ac. Head-to-head clinical trials demonstrate that radiolabeled SSTR antagonists such as [Ga]Ga-DOTA-JR11 and [Ga]Ga-DOTA-LM3 offer improved lesion detection and tumor-to-background ratios (particularly in liver metastases) compared to radiolabeled agonists like [Ga]Ga-DOTA-TOC and [Cu]Cu-DOTA-TATE.
View Article and Find Full Text PDFNutrient quality, environmental impact, and cost of Chinese diets: a benchmarking optimization approach.
Eur J Nutr
August 2025
Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.
Purpose: Design Chinese diets that are more nutritious, and have lower environmental footprints and cost, while accounting for diet preference.
Methods: Food consumption data of 4889 men and 5435 women adults were collected via 3-d 24-h dietary recalls in five regional subgroups (Metropolitan cities, Northeast, East, Southwest, and Central region) covered by the China Health and Nutrition Survey 2011. Data envelopment analysis (DEA) model was applied to benchmark diets that had higher adherence to food-based dietary guidelines.
Mortality predicting models for patients with infective endocarditis: a machine learning approach.
BMC Med Inform Decis Mak
July 2025
Department of Geriatric Intensive Medicine, Guangdong Provincial Geriatrics Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, 106 Zhongshan Er Road, Guangzhou, 510100, China.
Background: Infective endocarditis (IE) is a fatal cardiovascular disease with varied clinical manifestations but rapid progression. A series of existing risk models helped identify IE patients with high risk, but the imperfect predictive performance and limited application called for better predictive systems.
Methods: The single-centered, retrospective observational study applied four machine learning methods for predictive model construction: LASSO logistic regression, random forest (RF), support vector machine (SVM), and k-nearest neighbors (KNN).
Complement dysregulation at lymphatics.
J Allergy Clin Immunol
August 2025
Division of Allergy and Immunology, Department of Pediatrics, Marmara University School of Medicine, Istanbul, Turkey; Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey; Istanbul Jeffrey Modell Diagnostic Center for Primary Immunodeficiency Diseases, Istanbul, Turkey.
The complement system is a central component of innate immunity, orchestrating pathogen clearance while regulating inflammation, tissue repair, and homeostasis. Its activation is tightly controlled by multiple inhibitors to prevent self-damage. However, complement dysregulation is implicated in numerous organ-specific diseases, including paroxysmal nocturnal hemoglobinuria (erythrocytes), atypical hemolytic uremic syndrome (kidneys), and age-related macular degeneration (eyes).
View Article and Find Full Text PDFThe patient experience of CHAPLE disease: results from interviews conducted as part of a clinical trial for an ultra-rare condition.
Orphanet J Rare Dis
February 2025
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Background: CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) disease is a newly identified condition with an estimated worldwide prevalence of < 100 patients. Patient interviews can ensure that what is important to patients is assessed in a clinical trial program. Due to the rare and potentially fatal nature of CHAPLE disease, interviews were conducted as part of the pozelimab clinical trial, rather than in a separate study before the trial.
View Article and Find Full Text PDF